Anteris Technologies Global Corp. (AVR)
AU — Healthcare Sector
Automate Your Wheel Strategy on AVR
With Tiblio's Option Bot, you can configure your own wheel strategy including AVR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVR
- Rev/Share 0.1051
- Book/Share 1.0193
- PB 5.6754
- Debt/Equity 0.1151
- CurrentRatio 2.4149
- ROIC -1.5471
- MktCap 211866424.0
- FreeCF/Share -3.161
- PFCF -2.8428
- PE -1.6445
- Debt/Assets 0.0704
- DivYield 0
- ROE -2.5222
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AVR | Lake Street | -- | Buy | -- | $20 | Jan. 8, 2025 |
| Initiation | AVR | Barclays | -- | Overweight | -- | $22 | Jan. 7, 2025 |
| Initiation | AVR | Cantor Fitzgerald | -- | Overweight | -- | $9 | Jan. 7, 2025 |
| Initiation | AVR | TD Cowen | -- | Buy | -- | $15 | Jan. 7, 2025 |
News
About Anteris Technologies Global Corp. (AVR)
- IPO Date 2024-12-13
- Website https://anteristech.com
- Industry Medical - Devices
- CEO Wayne Geoffrey Paterson
- Employees 136
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.